Krystal Biotech, Inc. KRYS Business Segments — Net Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s business segments — net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s business segments — net income?
- Krystal Biotech, Inc. (KRYS) reported business segments — net income of $55.93M in Q1 2026.
- How has Krystal Biotech, Inc.'s business segments — net income changed year-over-year?
- Krystal Biotech, Inc.'s business segments — net income increased by 56.5% year-over-year, from $35.73M to $55.93M.
- What is the long-term trend for Krystal Biotech, Inc.'s business segments — net income?
- Over 3 years (2022 to 2025), Krystal Biotech, Inc.'s business segments — net income has grown at a 13.5% compound annual growth rate (CAGR), from -$139.98M to $204.83M.
- What does business segments — net income mean?
- The final profit or loss after all costs and taxes are subtracted.
- How do you interpret business segments — net income?
- Consistent growth in net income is the primary indicator of long-term financial health and shareholder value creation.
- How does business segments — net income compare across companies?
- The most widely used metric for comparing overall financial performance across all industries.